Denise A. Sarkozy
Research Subjects
Research Interests
Denise A. Sarkozy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daniel A. Scott
Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA
2 shared publications - Peter C. Giardina
Vaccine Research and Development, Pfizer Inc, Pearl River, New York
2 shared publications Allison Thompson
1 shared publication- Bogusław Tetiurka
NZOZ Salmed, Poradnia, Leczna, Poland
1 shared publication Douglas Girgenti
1 shared publication- Emilio A. Emini
Pfizer Inc, Collegeville, PA, USA
1 shared publication
Latest Publications
- 1 June 2013
- Vol. 33 (6) , 414-21
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.
To assess the safety and immune responses induced by a 13-valent pneumococcal conjugate vaccine (PCV13) after immunization of infants in Mexico. PCV13 was given with other routine childhood vaccinations to 225 infants in Mexico at ages 2, 4, 6, and 12 months. The proportions of subjects achieving immunoglobulin G (IgG) concentrations ≥0.35 µg/mL after the infant series and toddler dose were ≥93.1% and ≥96.7%, respectively, for all 13 serotypes. The serotype-specific pneumococcal IgG geometric mean concentrations after the infant series and toddler dose ranged from 1.18 to 9.13 µg/mL and from 1.62 to 15.41 µg/mL, respectively. The most common local reaction and systemic event after each dose were tenderness and irritability, respectively. Most fever was mild; no fever >40.0°C (i.e., severe) was reported. One subject withdrew because of Kawasaki disease 5 days after the first dose of vaccines, but this condition was not considered related to PCV13. Overall, PCV13 administered with routine pediatric vaccines was immunogenic and safe in healthy infants in Mexico.
- 1 June 2013
- Vol. 33 (6) , 414-21
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico.
To assess the safety and immune responses induced by a 13-valent pneumococcal conjugate vaccine (PCV13) after immunization of infants in Mexico. PCV13 was given with other routine childhood vaccinations to 225 infants in Mexico at ages 2, 4, 6, and 12 months. The proportions of subjects achieving immunoglobulin G (IgG) concentrations ≥0.35 µg/mL after the infant series and toddler dose were ≥93.1% and ≥96.7%, respectively, for all 13 serotypes. The serotype-specific pneumococcal IgG geometric mean concentrations after the infant series and toddler dose ranged from 1.18 to 9.13 µg/mL and from 1.62 to 15.41 µg/mL, respectively. The most common local reaction and systemic event after each dose were tenderness and irritability, respectively. Most fever was mild; no fever >40.0°C (i.e., severe) was reported. One subject withdrew because of Kawasaki disease 5 days after the first dose of vaccines, but this condition was not considered related to PCV13. Overall, PCV13 administered with routine pediatric vaccines was immunogenic and safe in healthy infants in Mexico.